NorthWest Biotherapeutics Inc (NWBO)

[CrashOverride]

That's right Bright Boy. NICE obviously needs the trial data for their QALY analysis but they will definitely fully reimburse DCVax given Hugh thresholds for orphan and rare diseases. This data was likely shared with NICE long ago while NICE can begin their assessment before MAA submission as long as MAA will be issued during their assessment process.

I believe that NWBO can charge up to 300K over three years and get full reimbursement given the maximum 100K per QALY threshold. Though I believe managment will want to price this vaccine much lower at 100K for three years of doses which would be easily reimbursable under NICE guidelines. Lower price will make the vaccine more accessible to patients especially in a single payer health system.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169141878